Dataset Preview
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code: DatasetGenerationError
Exception: ArrowInvalid
Message: JSON parse error: Column() changed from object to string in row 0
Traceback: Traceback (most recent call last):
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 174, in _generate_tables
df = pandas_read_json(f)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 38, in pandas_read_json
return pd.read_json(path_or_buf, **kwargs)
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 815, in read_json
return json_reader.read()
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1025, in read
obj = self._get_object_parser(self.data)
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1051, in _get_object_parser
obj = FrameParser(json, **kwargs).parse()
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1187, in parse
self._parse()
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/io/json/_json.py", line 1402, in _parse
self.obj = DataFrame(
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/frame.py", line 778, in __init__
mgr = dict_to_mgr(data, index, columns, dtype=dtype, copy=copy, typ=manager)
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/internals/construction.py", line 503, in dict_to_mgr
return arrays_to_mgr(arrays, columns, index, dtype=dtype, typ=typ, consolidate=copy)
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/internals/construction.py", line 114, in arrays_to_mgr
index = _extract_index(arrays)
File "/src/services/worker/.venv/lib/python3.9/site-packages/pandas/core/internals/construction.py", line 677, in _extract_index
raise ValueError("All arrays must be of the same length")
ValueError: All arrays must be of the same length
During handling of the above exception, another exception occurred:
Traceback (most recent call last):
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1815, in _prepare_split_single
for _, table in generator:
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 692, in wrapped
for item in generator(*args, **kwargs):
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 177, in _generate_tables
raise e
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/packaged_modules/json/json.py", line 151, in _generate_tables
pa_table = paj.read_json(
File "pyarrow/_json.pyx", line 308, in pyarrow._json.read_json
File "pyarrow/error.pxi", line 154, in pyarrow.lib.pyarrow_internal_check_status
File "pyarrow/error.pxi", line 91, in pyarrow.lib.check_status
pyarrow.lib.ArrowInvalid: JSON parse error: Column() changed from object to string in row 0
The above exception was the direct cause of the following exception:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1451, in compute_config_parquet_and_info_response
parquet_operations, partial, estimated_dataset_info = stream_convert_to_parquet(
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 994, in stream_convert_to_parquet
builder._prepare_split(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1702, in _prepare_split
for job_id, done, content in self._prepare_split_single(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1858, in _prepare_split_single
raise DatasetGenerationError("An error occurred while generating the dataset") from e
datasets.exceptions.DatasetGenerationError: An error occurred while generating the datasetNeed help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
id string | ID string | context string | task_type string | question string | options list | answer string |
|---|---|---|---|---|---|---|
0 | 04276-Interventions-001 | pmc.ncbi_PMC5290054 | Interventions | What type of intervention was used in the treatment group? | [
"A. Lactobacillus casei strain Shirota fermented milk",
"B. Yogurt",
"C. Regular milk",
"D. Probiotic capsules"
] | A |
1 | 04276-Interventions-002 | pmc.ncbi_PMC5290054 | Interventions | What was the main characteristic of the control group in the study? | [
"A. Probiotic fermented milk",
"B. Control milk",
"C. Lactobacillus casei strain Shirota",
"D. Fermented yogurt"
] | B |
2 | 04276-Methods-001 | pmc.ncbi_PMC5290054 | Methods | What type of study design was used in this research? | [
"A. Cohort study",
"B. Randomised controlled trial",
"C. Case-control study",
"D. Cross-sectional study"
] | B |
3 | 04276-Methods-002 | pmc.ncbi_PMC5290054 | Methods | What was the duration of the study? | [
"A. 8 weeks",
"B. 12 weeks",
"C. 16 weeks",
"D. 6 weeks"
] | B |
4 | 04276-Methods-003 | pmc.ncbi_PMC5290054 | Methods | How many participants were excluded postrandomisation? | [
"A. 1",
"B. 2",
"C. 3",
"D. 4"
] | C |
5 | 04276-Methods-004 | pmc.ncbi_PMC5290054 | Methods | How many participants were lost to follow‐up during the study? | [
"A. 0",
"B. 1",
"C. 2",
"D. 3"
] | A |
6 | 04276-Methods-005 | pmc.ncbi_PMC5290054 | Methods | In the study, how many participants were excluded from the probiotic bacteria group? | [
"A. 0",
"B. 1",
"C. 2",
"D. 3"
] | B |
7 | 04276-Participants-001 | pmc.ncbi_PMC5290054 | Participants | What is the total number of participants in the RCT study? | [
"A. 80",
"B. 90",
"C. 100",
"D. 110"
] | C |
8 | 04276-Participants-002 | pmc.ncbi_PMC5290054 | Participants | How many participants were in the probiotic bacteria group? | [
"A. 30",
"B. 50",
"C. 70",
"D. 100"
] | B |
9 | 04276-Participants-003 | pmc.ncbi_PMC5290054 | Participants | In what age range were the participants of the study? | [
"A. 20 to 29 years",
"B. 30 to 49 years",
"C. 50 to 69 years",
"D. 70 to 89 years"
] | B |
10 | 04276-Participants-004 | pmc.ncbi_PMC5290054 | Participants | Which country did the participants of the RCT study reside in? | [
"A. South Korea",
"B. Japan",
"C. China",
"D. Taiwan"
] | B |
11 | 04276-Participants-005 | pmc.ncbi_PMC5290054 | Participants | What type of workplace setting were participants recruited from? | [
"A. Factories",
"B. Retail stores",
"C. Office buildings",
"D. Remote locations"
] | C |
12 | 04276-Participants-006 | pmc.ncbi_PMC5290054 | Participants | Which of the following was an exclusion criterion for participants in the study? | [
"A. Being a healthy male worker",
"B. Living in Tokyo or its suburbs",
"C. Having a history of influenza vaccination in the last 6 months",
"D. Being between 30 to 49 years old"
] | C |
13 | 04276-Participants-007 | pmc.ncbi_PMC5290054 | Participants | How many participants were in the placebo group? | [
"A. 20",
"B. 30",
"C. 50",
"D. 60"
] | C |
14 | 04276-Participants-008 | pmc.ncbi_PMC5290054 | Participants | Which of the following health conditions would exclude a participant from the study? | [
"A. Headaches",
"B. Pollinosis",
"C. Fatigue",
"D. Mild allergies"
] | B |
15 | 04276-Participants-009 | pmc.ncbi_PMC5290054 | Participants | What was one requirement for participants regarding their location of work? | [
"A. Must work in a home office",
"B. Must work in a factory",
"C. Must work inside an office building",
"D. Must work remotely"
] | C |
16 | 04276-Participants-010 | pmc.ncbi_PMC5290054 | Participants | How often could participants work outside the office building to remain eligible for the study? | [
"A. Once a week",
"B. Twice a week or more",
"C. Not at all",
"D. Three times a week"
] | B |
17 | 04276-Outcomes-001 | pmc.ncbi_PMC5290054 | Outcomes | What is the primary outcome measured in the RCT study? | [
"A. NK cell activity",
"B. Level of immunoglobulin A (IgA) in saliva",
"C. Incidence of URTIs",
"D. Overall health improvement"
] | C |
18 | 04276-Outcomes-002 | pmc.ncbi_PMC5290054 | Outcomes | Which of the following is a secondary endpoint in the RCT study? | [
"A. Incidence of URTIs",
"B. Quality of life assessment",
"C. NK cell activity",
"D. Mortality rates"
] | C |
19 | 04276-Outcomes-003 | pmc.ncbi_PMC5290054 | Outcomes | In the context of the study, which substance's level is being measured in saliva as a secondary endpoint? | [
"A. Cytokines",
"B. Immunoglobulin A (IgA)",
"C. Immunoglobulin M (IgM)",
"D. T helper cells"
] | B |
20 | 06891-Patient Sampling-001 | pmc.ncbi_PMC3914762 | Patient Sampling | What percentage of the patients in cohort 2 were male? | [
"A. 50%",
"B. 76%",
"C. 64%",
"D. 82%"
] | B |
21 | 06891-Patient Sampling-002 | pmc.ncbi_PMC3914762 | Patient Sampling | How many healthy controls were included in cohort 2? | [
"A. 50",
"B. 25",
"C. 91",
"D. 23"
] | B |
22 | 15638-Methods-001 | pmc.ncbi_PMC2898909 | Methods | What type of study design was used in this RCT? | [
"A. Cohort study",
"B. Cross-sectional study",
"C. Randomized Controlled Trial (RCT)",
"D. Case-control study"
] | C |
23 | 15638-Methods-002 | pmc.ncbi_PMC2898909 | Methods | What was the follow-up duration after randomization? | [
"A. 1 month",
"B. 6 months",
"C. 3 months",
"D. 1 year"
] | A |
24 | 15638-Methods-003 | pmc.ncbi_PMC2898909 | Methods | What was the attrition rate observed in the study? | [
"A. 10%",
"B. 19%",
"C. 25%",
"D. 5%"
] | B |
25 | 15638-Methods-004 | pmc.ncbi_PMC2898909 | Methods | Did the attrition rates significantly differ across study conditions? | [
"A. Yes they differed significantly",
"B. No they did not differ significantly",
"C. They were not recorded",
"D. Yes they were equal"
] | B |
26 | 15638-Methods-005 | pmc.ncbi_PMC2898909 | Methods | Was an intention-to-treat (ITT) analysis performed? | [
"A. Yes",
"B. No",
"C. Only for some groups",
"D. Information not provided"
] | B |
27 | 15638-Methods-006 | pmc.ncbi_PMC2898909 | Methods | At what level was randomization conducted in this study? | [
"A. Community level",
"B. Group level",
"C. Individual level",
"D. Family level"
] | C |
28 | 15638-Methods-007 | pmc.ncbi_PMC2898909 | Methods | Was the clustering effect adjusted in this study? | [
"A. Yes",
"B. No",
"C. Only partially",
"D. Cannot be determined"
] | B |
29 | 15638-Participants-001 | pmc.ncbi_PMC2898909 | Participants | What was the total number of participants that were randomly assigned in the RCT study? | [
"A. 375",
"B. 385",
"C. 335",
"D. 113"
] | B |
30 | 15638-Participants-002 | pmc.ncbi_PMC2898909 | Participants | How many participants actually participated in the RCT study? | [
"A. 375",
"B. 113",
"C. 385",
"D. 335"
] | A |
31 | 15638-Participants-003 | pmc.ncbi_PMC2898909 | Participants | How many participants were included in the analyzed sample of the study? | [
"A. 375",
"B. 113",
"C. 335",
"D. 385"
] | C |
32 | 15638-Participants-004 | pmc.ncbi_PMC2898909 | Participants | What was the average age of participants in the study? | [
"A. 15 years",
"B. 16 years",
"C. 17 years",
"D. 18 years"
] | C |
33 | 15638-Participants-005 | pmc.ncbi_PMC2898909 | Participants | What percentage of participants in the study identified as male? | [
"A. 30%",
"B. 43%",
"C. 53%",
"D. 60%"
] | B |
34 | 15638-Participants-006 | pmc.ncbi_PMC2898909 | Participants | Which ethnic group had the highest representation among the participants? | [
"A. Hispanic",
"B. Black",
"C. White",
"D. Asian"
] | C |
35 | 15638-Participants-007 | pmc.ncbi_PMC2898909 | Participants | What percentage of participants reported alcohol use over the past 30 days? | [
"A. 30%",
"B. 40%",
"C. 44%",
"D. 50%"
] | C |
36 | 15638-Participants-008 | pmc.ncbi_PMC2898909 | Participants | In which country was the RCT study conducted? | [
"A. Canada",
"B. Australia",
"C. United Kingdom",
"D. United States"
] | D |
37 | 15638-Interventions-001 | pmc.ncbi_PMC2898909 | Interventions | What is the primary focus of Intervention-1: Goal Survey? | [
"A. To help students develop contracts for goal setting",
"B. To influence multiple health habits by addressing images of college and career success",
"C. To provide consultative feedback for personal development",
"D. To decrease smoking rates among young adults"
] | B |
38 | 15638-Interventions-002 | pmc.ncbi_PMC2898909 | Interventions | What additional component does Intervention-2 include compared to Intervention-1? | [
"A. Consultative feedback",
"B. Printed text",
"C. A contract to help students select goals",
"D. Scripted messages"
] | C |
39 | 15638-Interventions-003 | pmc.ncbi_PMC2898909 | Interventions | What is the main objective of Intervention-3: Goal Survey + Consult? | [
"A. To address images of successful young adults",
"B. To provide image-based feedback tailored to personal development and health behaviors",
"C. To avoid alcohol and tobacco use",
"D. To influence multiple health habits"
] | B |
40 | 15638-Interventions-004 | pmc.ncbi_PMC2898909 | Interventions | What is the duration of the interventions described in the study? | [
"A. 2 months",
"B. 4 weeks",
"C. 1 month",
"D. 6 weeks"
] | C |
41 | 15638-Outcomes-001 | pmc.ncbi_PMC2898909 | Outcomes | What was the p-value for the difference in intention to use alcohol between Int‐1 and Int‐2? | [
"A. p=0.05",
"B. p<0.001",
"C. p=0.13",
"D. p=0.82"
] | B |
42 | 15638-Outcomes-002 | pmc.ncbi_PMC2898909 | Outcomes | What was the average length of alcohol use score for Int‐2? | [
"A. 2.69±0.2",
"B. 2.47±0.2",
"C. 2.61±0.2",
"D. 3.32±0.3"
] | B |
43 | 15638-Outcomes-003 | pmc.ncbi_PMC2898909 | Outcomes | What was the p-value for the comparison of the length of alcohol use scores across the three interventions? | [
"A. p=0.05",
"B. p<0.001",
"C. p=0.13",
"D. p=0.82"
] | A |
44 | 15638-Outcomes-004 | pmc.ncbi_PMC2898909 | Outcomes | What was the average score for 30-day alcohol frequency for Int‐3? | [
"A. 1.91±0.1",
"B. 1.74±0.1",
"C. 1.81±0.1",
"D. 2.69±0.2"
] | C |
45 | 15638-Outcomes-005 | pmc.ncbi_PMC2898909 | Outcomes | What was the p-value for the 30-day alcohol frequency score comparison? | [
"A. p=0.05",
"B. p<0.001",
"C. p=0.13",
"D. p=0.82"
] | C |
46 | 15638-Outcomes-006 | pmc.ncbi_PMC2898909 | Outcomes | What was the average quantity of alcohol consumed over 30 days for Int‐1? | [
"A. 3.27±0.3",
"B. 3.32±0.3",
"C. 3.42±0.3",
"D. 2.69±0.2"
] | A |
47 | 15638-Outcomes-007 | pmc.ncbi_PMC2898909 | Outcomes | What was the p-value for the comparison of 30-day alcohol quantity across interventions? | [
"A. p=0.05",
"B. p<0.001",
"C. p=0.13",
"D. p=0.82"
] | D |
48 | 11397-Methods-001 | pmc.ncbi_PMC2639595 | Methods | What was the randomisation ratio used in the study? | [
"A. 1:1",
"B. 2:1",
"C. 3:1",
"D. 4:1"
] | B |
49 | 11397-Participants-001 | pmc.ncbi_PMC2639595 | Participants | How many healthy adults were self-referred to participate in the study? | [
"A. 4000",
"B. 5200",
"C. 6203",
"D. 7200"
] | C |
50 | 11397-Interventions-001 | pmc.ncbi_PMC2639595 | Interventions | How many types of viruses were included in the TIV vaccine's haemagglutinin antigens? | [
"A. One",
"B. Two",
"C. Three",
"D. Four"
] | C |
51 | 11397-Interventions-002 | pmc.ncbi_PMC2639595 | Interventions | When did passive surveillance for influenza-like illness (ILI) symptoms begin after vaccination? | [
"A. On the day of vaccination",
"B. One week after vaccination",
"C. Two weeks after vaccination",
"D. One month after vaccination"
] | A |
52 | 11397-Interventions-003 | pmc.ncbi_PMC2639595 | Interventions | How often did active surveillance contact participants after vaccination? | [
"A. Daily",
"B. Weekly",
"C. Biweekly",
"D. Monthly"
] | C |
53 | 11397-Interventions-004 | pmc.ncbi_PMC2639595 | Interventions | Was it reported whether the surveillance methods included the entire cohort or just a subset? | [
"A. Yes",
"B. No",
"C. Only for active surveillance",
"D. Only for passive surveillance"
] | B |
54 | 11397-Interventions-005 | pmc.ncbi_PMC2639595 | Interventions | What was the method of self-reporting ILI symptoms for participants during passive surveillance? | [
"A. Through an online form",
"B. Via email",
"C. Through a toll-free number",
"D. In-person interviews"
] | C |
55 | 11397-Outcomes-001 | pmc.ncbi_PMC2639595 | Outcomes | What was the blood sample collection timeline for the serological outcomes in this study? | [
"A. Prior to vaccination and 21 days post-vaccination",
"B. Only after vaccination",
"C. Immediately after vaccination",
"D. 7 days before vaccination"
] | A |
56 | 11397-Outcomes-002 | pmc.ncbi_PMC2639595 | Outcomes | How many reported influenza-like illness (ILI) episodes were there in the study? | [
"A. 370",
"B. 814",
"C. 46",
"D. 240"
] | B |
57 | 11397-Outcomes-003 | pmc.ncbi_PMC2639595 | Outcomes | What was the total number of ILI events reported among TIV participants? | [
"A. 120",
"B. 370",
"C. 254",
"D. 814"
] | C |
58 | 11397-Outcomes-004 | pmc.ncbi_PMC2639595 | Outcomes | For the effectiveness outcomes, what was stored at 28 °C before being sent to the National Reference Laboratory? | [
"A. Blood samples",
"B. Serum samples",
"C. Nasal and throat swabs",
"D. Influenza vaccines"
] | C |
59 | 11397-Outcomes-005 | pmc.ncbi_PMC2639595 | Outcomes | What was the criteria for defining a new ILI episode in this study? | [
"A. At least 5 days free of symptoms",
"B. At least 3 days free of symptoms",
"C. At least 7 days free of symptoms",
"D. At least 10 days free of symptoms"
] | C |
60 | 11397-Outcomes-006 | pmc.ncbi_PMC2639595 | Outcomes | How many serious adverse events (SAEs) were solicited in the safety data collection? | [
"A. From all participants",
"B. From a randomly selected subset of participants",
"C. Only from TIV participants",
"D. Only from placebo participants"
] | B |
61 | 11397-Outcomes-007 | pmc.ncbi_PMC2639595 | Outcomes | What scale was used to grade the intensity of reactogenicity symptoms? | [
"A. 0 to 5 grade scale",
"B. 0 to 10 grade scale",
"C. 0 to 3 grade scale",
"D. 1 to 4 grade scale"
] | C |
62 | 11397-Outcomes-008 | pmc.ncbi_PMC2639595 | Outcomes | What was not considered a primary outcome in this study? | [
"A. Reactogenicity",
"B. Safety",
"C. Serology",
"D. Effectiveness"
] | C |
63 | 09475-Methods-001 | spring_s00383-009-2437-4 | Methods | How was data collected for this study? | [
"A. Through interviews",
"B. Via a self-reported questionnaire",
"C. From hospital records",
"D. Using online surveys"
] | B |
64 | 09475-Participants-001 | spring_s00383-009-2437-4 | Participants | What was the minimum age of participants included in the study? | [
"A. 12 years",
"B. 16 years",
"C. 18 years",
"D. 20 years"
] | B |
65 | 09475-Interventions-001 | spring_s00383-009-2437-4 | Interventions | What type of surgical intervention was compared to pharmacologic treatment in the study? | [
"A. Appendectomy",
"B. Laparoscopic surgery",
"C. Restorative proctocolectomy with ileoanal anastomosis",
"D. Colostomy"
] | C |
66 | 09475-Outcomes-001 | spring_s00383-009-2437-4 | Outcomes | How was infertility defined in this study? | [
"A. Not using contraceptives",
"B. Not becoming pregnant within 6 months",
"C. Not becoming pregnant within 12 months",
"D. Being unable to conceive after 2 years"
] | C |
67 | 08446-Methods-001 | pmc.ncbi_PMC3740324 | Methods | What type of study design was used in this RCT? | [
"A. Case-control study",
"B. Parallel-group randomized controlled trial",
"C. Cohort study",
"D. Cross-sectional study"
] | B |
68 | 08446-Methods-002 | pmc.ncbi_PMC3740324 | Methods | How many total participants were randomized in this study? | [
"A. 50",
"B. 99",
"C. 100",
"D. 149"
] | C |
69 | 08446-Methods-003 | pmc.ncbi_PMC3740324 | Methods | How many participants were in the loading group? | [
"A. 49",
"B. 50",
"C. 1",
"D. 99"
] | B |
70 | 08446-Methods-004 | pmc.ncbi_PMC3740324 | Methods | How many participants were analyzed after randomization? | [
"A. 50",
"B. 49",
"C. 99",
"D. 100"
] | C |
71 | 08446-Methods-005 | pmc.ncbi_PMC3740324 | Methods | What was the unit of analysis in this study? | [
"A. Study center",
"B. Study eye per participant",
"C. Group of participants",
"D. Clinical outcome"
] | B |
72 | 08446-Methods-006 | pmc.ncbi_PMC3740324 | Methods | Were there any reported losses to follow-up in this study? | [
"A. Yes 1 participant",
"B. No none reported",
"C. Yes 50 participants",
"D. Yes all participants"
] | B |
73 | 08446-Methods-007 | pmc.ncbi_PMC3740324 | Methods | How was the analysis of participants conducted in this study? | [
"A. As treated",
"B. Intention-to-treat",
"C. Per-protocol",
"D. Convenience sample"
] | B |
74 | 08446-Methods-008 | pmc.ncbi_PMC3740324 | Methods | What was the reason for the selected sample size in the study? | [
"A. To achieve a high power",
"B. Due to a significant expected effect",
"C. A reasonable and pragmatic sample size for a monocentric study",
"D. Based on previous literature"
] | C |
75 | 08446-Participants-001 | pmc.ncbi_PMC3740324 | Participants | What percentage of the participants in the study were women? | [
"A. 60%",
"B. 73%",
"C. 50%",
"D. 80%"
] | B |
76 | 08446-Participants-002 | pmc.ncbi_PMC3740324 | Participants | How many participants were aged between 61 and 70 years? | [
"A. 51",
"B. 13",
"C. 35",
"D. 10"
] | B |
77 | 08446-Participants-003 | pmc.ncbi_PMC3740324 | Participants | What is the maximum age range of the participants reported in the study? | [
"A. 61-80 years",
"B. 71-81 years",
"C. ≥ 81 years",
"D. 61-70 years"
] | C |
78 | 08446-Participants-004 | pmc.ncbi_PMC3740324 | Participants | Which condition is NOT included in the exclusion criteria for participants? | [
"A. Active intraocular inflammation",
"B. Ocular hypertension (IOP > 25 mmHg)",
"C. Treatment-naïve status",
"D. Allergy to fluorescein"
] | C |
79 | 08446-Participants-005 | pmc.ncbi_PMC3740324 | Participants | According to the study, which condition was included in the exclusion criteria? | [
"A. Prescription of ≤ 2 antihypertensive medications",
"B. Uncontrolled hypertension",
"C. Presence of AMD",
"D. Age ≥ 61 years"
] | B |
80 | 08446-Participants-006 | pmc.ncbi_PMC3740324 | Participants | What aspect of baseline characteristics was reported to be equivalent between groups? | [
"A. Mean age",
"B. Mean VAs and mean CMT",
"C. Gender distribution",
"D. Number of participants"
] | B |
81 | 08446-Interventions-001 | pmc.ncbi_PMC3740324 | Interventions | What is the dosage of intravitreous bevacizumab used in the study? | [
"A. 0.5 mg",
"B. 1.25 mg",
"C. 2.5 mg",
"D. 5 mg"
] | B |
82 | 08446-Interventions-002 | pmc.ncbi_PMC3740324 | Interventions | How frequently was the second intervention administered during the initial phase? | [
"A. Every week",
"B. Every 2 weeks",
"C. Every 4 weeks",
"D. Every 6 weeks"
] | C |
83 | 08446-Interventions-003 | pmc.ncbi_PMC3740324 | Interventions | What is the duration of the follow-up period for the study? | [
"A. 26 weeks",
"B. 36 weeks",
"C. 54 weeks",
"D. 72 weeks"
] | C |
84 | 08446-Interventions-004 | pmc.ncbi_PMC3740324 | Interventions | How often were assessments for retreatment scheduled? | [
"A. Every 4 weeks",
"B. Every 6 weeks",
"C. Every 8 weeks",
"D. Every 12 weeks"
] | B |
85 | 08446-Outcomes-001 | pmc.ncbi_PMC3740324 | Outcomes | What is the primary outcome in the RCT study? | [
"A. Proportion with visual improvement defined as gain of ≥ 15 letters from baseline",
"B. Proportion with visual stability defined as loss of ≤ 15 letters from baseline",
"C. Proportion with systemic adverse events",
"D. Proportion with ocular adverse events"
] | B |
86 | 08446-Outcomes-002 | pmc.ncbi_PMC3740324 | Outcomes | What is one of the secondary outcomes measured in the study? | [
"A. Visual acuity",
"B. CMT on OCT",
"C. Quality of life",
"D. Number of injections"
] | B |
87 | 08446-Outcomes-003 | pmc.ncbi_PMC3740324 | Outcomes | Which type of adverse events are reported in the study? | [
"A. Neurological and psychiatric adverse events",
"B. Ocular and systemic adverse events",
"C. Gastrointestinal adverse events",
"D. Respiratory and allergic adverse events"
] | B |
88 | 08446-Outcomes-004 | pmc.ncbi_PMC3740324 | Outcomes | Which outcomes were NOT reported in the study? | [
"A. Proportion with visual stability",
"B. CMT on OCT",
"C. Number of injections",
"D. Occurrence of adverse events"
] | C |
89 | 08446-Outcomes-005 | pmc.ncbi_PMC3740324 | Outcomes | At what intervals were outcomes assessed during the study? | [
"A. q2 weeks for 54 weeks",
"B. q4 weeks for 54 weeks",
"C. q6 weeks for 54 weeks",
"D. q8 weeks for 54 weeks"
] | C |
90 | 03163-Methods-001 | pmc.ncbi_PMC5909820 | Methods | What type of study design was used in the trial? | [
"A. Observational study",
"B. Cohort study",
"C. Randomized controlled trial",
"D. Case-control study"
] | C |
91 | 03163-Methods-002 | pmc.ncbi_PMC5909820 | Methods | How many centers were involved in the trial? | [
"A. One center",
"B. Two centers",
"C. Three centers",
"D. Four centers"
] | B |
92 | 03163-Participants-001 | pmc.ncbi_PMC5909820 | Participants | What is one of the inclusion criteria for participants in the RCT study? | [
"A. Aged between 60 and 74 years",
"B. ≥ 3 documented CDI recurrences",
"C. Previous FMT",
"D. A history of chronic diarrheal disorder"
] | B |
93 | 03163-Participants-002 | pmc.ncbi_PMC5909820 | Participants | Which of the following is an exclusion criterion for the RCT study participants? | [
"A. Completed ≥ 10 days of vancomycin therapy",
"B. Aged 50 years",
"C. History of inflammatory bowel disease",
"D. Did not maintain cure after vancomycin therapy"
] | C |
94 | 03163-Participants-003 | pmc.ncbi_PMC5909820 | Participants | How many days of vancomycin therapy must participants have completed for the most recent CDI prior to the intervention? | [
"A. 5 days",
"B. ≥ 10 days",
"C. 15 days",
"D. 20 days"
] | B |
95 | 03163-Participants-004 | pmc.ncbi_PMC5909820 | Participants | Which age group is excluded from participating in the RCT study? | [
"A. Aged 25-35 years",
"B. Aged 50-60 years",
"C. Aged ≥ 75 years",
"D. Aged 30-40 years"
] | C |
96 | 03163-Participants-005 | pmc.ncbi_PMC5909820 | Participants | What must participants not be able to have occurred to be included in the study relating to vancomycin treatment? | [
"A. Have recurrent diarrhea after treatment",
"B. Have not completed a course of vancomycin",
"C. Have an allergic reaction",
"D. Have a diagnosis of colorectal cancer"
] | A |
97 | 03163-Interventions-001 | pmc.ncbi_PMC5909820 | Interventions | What was the mean weight of the stool used in the fresh donor feces solution infusion? | [
"A. 50 g",
"B. 64 g",
"C. 70 g",
"D. 80 g"
] | B |
98 | 03163-Interventions-002 | pmc.ncbi_PMC5909820 | Interventions | How many participants received the autologous feces solution infusion? | [
"A. 20",
"B. 22",
"C. 24",
"D. 26"
] | C |
99 | 03163-Interventions-003 | pmc.ncbi_PMC5909820 | Interventions | What was the volume of the fresh donor feces solution infusion per treatment? | [
"A. 250 mL",
"B. 300 mL",
"C. 500 mL",
"D. 600 mL"
] | C |
End of preview.
YAML Metadata Warning:empty or missing yaml metadata in repo card
Check out the documentation for more information.
The dataset is derived exclusively from publicly available sources (e.g., PubMed Central, Cochrane Review) and distributed under the original licenses. We ensure that redistribution complies with the terms of the respective licenses (e.g., CC-BY).
- Downloads last month
- 17